Clinical, hormonal, biochemical characteristics and prevalence of Polycystic Ovary Syndrome in women from the Coffee Region, Colombia, 2016-2020
PDF (Español (España))


Polycystic Ovary Syndrome

How to Cite

Espitia De La Hoz, F. J. . (2022). Clinical, hormonal, biochemical characteristics and prevalence of Polycystic Ovary Syndrome in women from the Coffee Region, Colombia, 2016-2020. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 9(4).


Objective: to estimate the prevalence and describe the frequency of the phenotypes and characterize the phenotypes of polycystic ovary syndrome (PCOS) in women from the Coffee Region.

Materials and methods: cross-sectional study, in 837 women aged 18 to 35 years. Women who strictly met the established Rotterdam consensus criteria for PCOS at the time of care, menarche of at least 3 years prior to enrollment, and non-users of hormonal contraceptives were included; in three reference university institutions located in the Coffee Region (Armenia, Pereira and Manizales), Colombia; between 2016 and 2020. The women underwent clinical evaluation, blood biochemistry, and transvaginal pelvic ultrasound to fit the Rotterdam consensus criteria. Descriptive statistics were used. Simple random sampling.

Results: the mean age of the participants was 32.46 ± 5.19 years. The most representative group were those under 30 years of age. The prevalence of PCOS was 14.26%. 56.39% corresponded to phenotype A, followed by phenotype D (18.75%). 13.85% of the women did not present polycystic ovaries in the ultrasound study, and 18.75% did not report hyperandrogenism.

Conclusions: the prevalence of polycystic ovary syndrome is high in women from the Coffee Growing Region, with a predominance of phenotype A. More efforts and education are required for professionals to achieve standardization of diagnostic criteria, in order to establish both the prevalence and the phenotypic characterization of PCOS throughout Colombia.
PDF (Español (España))


Meier RK. Polycystic Ovary Syndrome. Nurs Clin North Am. 2018 sept.;53(3):407-20.

Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed). 2014 en. 1;6:104-19.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 en.;81(1):19-25.

Bharathi R, Swetha S, Neerajaa J, Madhavica JV, Janani DM, Rekha SN, et al. An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population. Middle East Fertil Soc J. 2017;22(4):313-6.

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 jun.;89(6):2745-9.

Builes CA, Díaz I, Castañeda J, Pérez LE. Caracterización clínica y bioquímica de la mujer con Síndrome de Ovario Poliquístico. Rev Colomb Obstet Ginecol. 2006;57(1):36-40.

Daniels TL, Berga SL. Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. J Clin Endocrinol Metab. 1997 dic.;82(12):4179-83.

Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest. 1976 my.;57(5):1320-9.

Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013 abr.;98(4):E628-37.

Sir-Petermann T, Maliqueo M, Codner E, Echiburú B, Crisosto N, Pérez V, et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007 dic.;92(12):4637-42.

Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod. 2009 jul.;24(7):1548-55.

Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003 sept. 27;362(9389):1017-21.

ACOG Practice Bulletin Summary, Number 194. Polycystic Ovary Syndrome. Obstet Gynecol. 2018 jun.;131(6):1174-6.

Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013 dic. 18;6:1-13.

Pasquali R, Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann NY Acad Sci. 2006 dic.;1092:158-74.

O'Brien B, Dahiya R, Kimble R. Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome. BMJ Case Rep. 2020 abr. 9;13(4):e231749.

Neven AC, Laven J, Teede HJ, Boyle JA. A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin Reprod Med. 2018 en.;36(1):5-12.

Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016 jul.;106(1):6-15.

Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015 oct.;36(5):487-525.

Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 dic.;98(12):4565-92.

Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Oxford, England: Blackwell Scientific; 1992:377-84.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 febr.;91(2):456-88.

Johnson T, Kaplan L, Ouyang P, Rizza R. National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome (PCOS). NIH EbMW Report. 2013. Bethesda, Maryland: National Institutes of Health; 1-14.

Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 oct.;37(5):467-520.

Escobar-Morreale HF, Sanchón R, San Millán JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab. 2008 febr.;93(2):527-33.

Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 1996 ag.;81(8):2854-64.

Dewailly D, Catteau-Jonard S, Reyss AC, Maunoury-Lefebvre C, Poncelet E, Pigny P. The excess in 2-5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome. Hum Reprod. 2007 jun.;22(6):1562-6.

Zhu RY, Wong YC, Yong EL. Sonographic evaluation of polycystic ovaries. Best Pract Res Clin Obstet Gynaecol. 2016 nov.;37:25-37.

Youngster M, Ward VL, Blood EA, Barnewolt CE, Emans SJ, Divasta AD. Utility of ultrasound in the diagnosis of polycystic ovary syndrome in adolescents. Fertil Steril. 2014 nov.;102(5):1432-8.

Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961 nov.;21:1440-7.

Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016 dic.;31(12):2841-55.

Ganie MA, Rashid A, Sahu D, Nisar S, Wani IA, Khan J. Prevalence of polycystic ovary syndrome (PCOS) among reproductive age women from Kashmir valley: A cross-sectional study. Int J Gynaecol Obstet. 2020 my.;149(2):231-6.

Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of Polycystic Ovary Syndrome and Related Disorders in Mexican Women. Gynecol Obstet Invest 2010;69:274-80.

Pehlivanov B, Orbetzova M. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. Gynecol Endocrinol. 2007 oct.;23(10):604-9.

Vaggopoulos V, Trakakis E, Panagopoulos P, Basios G, Salloum I, Christodoulaki C, et al. The prevalence of phenotypic subgroups in Greek women with polycystic ovarian syndrome. Clin Exp Obstet Gynecol. 2013;40(2):253-6.

Amini P, Omani-Samani R, Hosseinib R, Ahmadi J, Maroufizadeh S. A cross-sectional comparison of clinical and endocrine parameters among phenotypes of polycystic ovarian syndrome in iranian population. Middle East Fert Soc J. 2018;23(4):425-30.

Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, et al. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril. 2016 nov.;106(6):1510-20.e2.

Mehta J, Kamdar V, Dumesic D. Phenotypic expression of polycystic ovary syndrome in South Asian women. Obstet Gynecol Surv. 2013 mzo.;68(3):228-34. Fe de erratas en: Obstet Gynecol Surv. 2013 my.;68(5):405.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2022 Revista Colombiana de Endocrinología, Diabetes & Metabolismo




Download data is not yet available.